AUROBINDO PHARMA Latest Share Price (AUROPHARMA)
TODAY IN ONE LINE
AUROPHARMA edged up 1.0% on light volume, in line with Nifty's 0.1% move, supported by recent strong earnings.
With a market cap of ₹95,127.23 Cr., it trades at a P/E of 25.84. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
AUROBINDO PHARMA flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Quarterly OutperformanceLatest quarter Sales up 226.9% and Profit up 40.0%
- ●Healthy Operating MarginsOPM is structurally strong at 16.3%
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.20x
- ●FII AccumulationFII holding increased by 1.14% QoQ
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Poor Capital ReturnsLow ROE of 9.3%
- ●Promoter SellingPromoter holding decreased by 48.75% QoQ
Latest AUROBINDO PHARMA News
What changed recently?
Recent events, corporate actions, and announcements.
AUROBINDO PHARMA valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for AUROBINDO PHARMA, framed against the sector median so the premium or discount is obvious at a glance.
AUROBINDO PHARMA trades at a P/E of 25.84× and P/B of 2.54×, against the Healthcare sector median P/E of 41.28×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
AUROBINDO PHARMA technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for AUROBINDO PHARMA — derived from the latest tape, not yesterday's close.
AUROBINDO PHARMA last traded at ₹1,653.1 with an intraday range of ₹1,622.6–₹1,661.5 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹1653.10| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 1746.67 | +93.57 | +5.66% |
| R3 | 1707.77 | +54.67 | +3.31% |
| R2 | 1684.63 | +31.53 | +1.91% |
| R1 | 1668.87 | +15.77 | +0.95% |
| PIVOT | 1645.73 | -7.37 | -0.45% |
| CURRENT | 1653.10 | — | — |
| S1 | 1629.97 | -23.13 | -1.40% |
| S2 | 1606.83 | -46.27 | -2.80% |
| S3 | 1591.07 | -62.03 | -3.75% |
| S4 | 1552.17 | -100.93 | -6.11% |
AUROPHARMA is trading Above CPR, indicating Bullishness
CPR is Average
Day's range: ₹1626–₹1644.9
Trading Inside opening range
AUROBINDO PHARMA financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for AUROBINDO PHARMA — consolidated or standalone — with margins, YoY growth and key ratios inline.
AUROBINDO PHARMA reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹95,127.23 Cr. and reported EPS of ₹17.95.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 31,724 | 33,653 ▲ 6.1% |
| Sales Growth YoY %Derived | 9.39% | 6.08% |
| Other Income | 622 | 492 ▼ 20.9% |
| Total Income | 32,346 | 34,145 ▲ 5.6% |
| 13,026 | 13,488 ▲ 3.5% | |
| Gross ProfitDerived | 18,697 | 20,165 ▲ 7.8% |
| Gross Margin %Derived | 58.94% | 59.92% |
| 12,115 | 13,319 ▲ 9.9% | |
| EBITDA (Operating Profit)Derived | 6,583 | 6,846 ▲ 4.0% |
| OPM %Derived | 20.75% | 20.34% |
| 2,107 | 2,097 ▼ 0.5% | |
| Profit Before Tax (PBT) | 5,098 | 5,110 ▲ 0.2% |
| 1,583 | 1,609 ▲ 1.7% | |
| Effective Tax %Derived | 31.05% | 31.48% |
| Total Profit for Period | 3,484 | 3,503 ▲ 0.6% |
| Less: Non-controlling Interests | -2 | -2 ▲ 22.9% |
| Net Profit (Owner's PAT)Derived | 3,486 | 3,505 ▲ 0.5% |
| Net Profit Margin %Derived | 10.99% | 10.41% |
| PAT Growth YoY %Derived | 9.86% | 0.54% |
| Earnings Per Share (EPS ₹) | 60.02 | 60.34 ▲ 0.5% |
| Diluted Shares Outstanding (Cr) | 58 | 58 ▲ 0.0% |
| Share of Profit from Associates/JVs | -32 | 2 ▲ 104.8% |
| Other Comprehensive Income (Net of Tax) | 304 | 1,965 ▲ 547.3% |
| Total Expenses (incl. D&A & Interest) | 27,248 | 29,035 ▲ 6.6% |
| Material Cost % of RevenueDerived | 33.84% | 30.62% |
| Employee Cost % of RevenueDerived | 14.11% | 15.42% |
| Other Cost % of RevenueDerived | 24.08% | 24.15% |
| Interest Coverage (x)Derived | 10.79x | 13.20x |
| Period | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 16,500 | 19,564 ▲ 18.6% | 23,099 ▲ 18.1% | 24,775 ▲ 7.3% | 23,455 ▼ 5.3% | 24,855 ▲ 6.0% | 29,002 ▲ 16.7% | 31,724 ▲ 9.4% | 33,653 ▲ 6.1% | |
| Sales Growth YoY %Derived | — | 18.57% | 18.07% | 7.26% | -5.32% | 5.97% | 16.68% | 9.39% | 6.08% | |
| Other Income | 102 | 116 ▲ 13.4% | 86 ▼ 25.5% | 381 ▲ 341.8% | 320 ▼ 15.9% | 291 ▼ 9.3% | 557 ▲ 91.8% | 622 ▲ 11.6% | 492 ▼ 20.9% | |
| Total Income | 16,602 | 19,679 ▲ 18.5% | 23,185 ▲ 17.8% | 25,155 ▲ 8.5% | 23,776 ▼ 5.5% | 25,146 ▲ 5.8% | 29,559 ▲ 17.6% | 32,346 ▲ 9.4% | 34,145 ▲ 5.6% | |
6,753 | 8,713 ▲ 29.0% | 9,735 ▲ 11.7% | 9,902 ▲ 1.7% | 10,140 ▲ 2.4% | 11,293 ▲ 11.4% | 12,603 ▲ 11.6% | 13,026 ▲ 3.4% | 13,488 ▲ 3.5% | ||
| Gross ProfitDerived | 9,747 | 10,851 ▲ 11.3% | 13,363 ▲ 23.2% | 14,872 ▲ 11.3% | 13,315 ▼ 10.5% | 13,562 ▲ 1.9% | 16,399 ▲ 20.9% | 18,697 ▲ 14.0% | 20,165 ▲ 7.8% | |
| Gross Margin %Derived | 59.07% | 55.46% | 57.85% | 60.03% | 56.77% | 54.56% | 56.54% | 58.94% | 59.92% | |
5,975 | 6,959 ▲ 16.5% | 8,539 ▲ 22.7% | 9,539 ▲ 11.7% | 8,928 ▼ 6.4% | 9,843 ▲ 10.2% | 10,556 ▲ 7.2% | 12,115 ▲ 14.8% | 13,319 ▲ 9.9% | ||
| EBITDA (Operating Profit)Derived | 3,772 | 3,892 ▲ 3.2% | 4,825 ▲ 24.0% | 5,333 ▲ 10.5% | 4,387 ▼ 17.7% | 3,719 ▼ 15.2% | 5,843 ▲ 57.1% | 6,583 ▲ 12.7% | 6,846 ▲ 4.0% | |
| OPM %Derived | 22.86% | 19.89% | 20.89% | 21.53% | 18.70% | 14.96% | 20.15% | 20.75% | 20.34% | |
636 | 743 ▲ 16.8% | 1,100 ▲ 48.2% | 3,944 ▲ 258.5% | 1,047 ▼ 73.5% | 1,385 ▲ 32.3% | 1,620 ▲ 16.9% | 2,107 ▲ 30.1% | 2,097 ▼ 0.5% | ||
| Profit Before Tax (PBT) | 3,238 | 3,089 ▼ 4.6% | 3,758 ▲ 21.7% | 7,399 ▲ 96.9% | 3,404 ▼ 54.0% | 2,624 ▼ 22.9% | 4,397 ▲ 67.6% | 5,098 ▲ 15.9% | 5,110 ▲ 0.2% | |
818 | 727 ▼ 11.2% | 914 ▲ 25.7% | 2,010 ▲ 120.0% | 726 ▼ 63.9% | 685 ▼ 5.6% | 1,211 ▲ 76.8% | 1,583 ▲ 30.7% | 1,609 ▲ 1.7% | ||
| Effective Tax %Derived | 25.27% | 23.53% | 24.31% | 27.16% | 21.32% | 26.10% | 27.54% | 31.05% | 31.48% | |
| Total Profit for Period | 2,423 | 2,365 ▼ 2.4% | 2,830 ▲ 19.7% | 5,334 ▲ 88.5% | 2,647 ▼ 50.4% | 1,928 ▼ 27.2% | 3,169 ▲ 64.4% | 3,484 ▲ 9.9% | 3,503 ▲ 0.6% | |
| Less: Non-controlling Interests | -0 | -0 ▲ 11.5% | -1 ▼ 534.8% | -1 ▲ 30.1% | -1 ▼ 2.0% | 0 ▲ 114.4% | -4 ▼ 2766.7% | -2 ▲ 42.3% | -2 ▲ 22.9% | |
| Net Profit (Owner's PAT)Derived | 2,423 | 2,365 ▼ 2.4% | 2,831 ▲ 19.7% | 5,335 ▲ 88.4% | 2,648 ▼ 50.4% | 1,928 ▼ 27.2% | 3,173 ▲ 64.6% | 3,486 ▲ 9.9% | 3,505 ▲ 0.5% | |
| Net Profit Margin %Derived | 14.69% | 12.09% | 12.26% | 21.53% | 11.29% | 7.75% | 10.94% | 10.99% | 10.41% | |
| PAT Growth YoY %Derived | — | -2.41% | 19.72% | 88.45% | -50.36% | -27.21% | 64.62% | 9.86% | 0.54% | |
| Earnings Per Share (EPS ₹) | 41.36 | 40.36 ▼ 2.4% | 48.32 ▲ 19.7% | 91.05 ▲ 88.4% | 45.20 ▼ 50.4% | 32.90 ▼ 27.2% | 54.15 ▲ 64.6% | 60.02 ▲ 10.8% | 60.34 ▲ 0.5% | |
| Diluted Shares Outstanding (Cr) | 59 | 59 ▲ 0.0% | 59 ▲ 0.0% | 59 ▲ 0.0% | 59 ▲ 0.0% | 59 ▲ 0.0% | 59 ▲ 0.0% | 58 ▼ 0.9% | 58 ▲ 0.0% | |
| Share of Profit from Associates/JVs | 3 | 3 ▼ 14.0% | -15 ▼ 661.9% | -55 ▼ 264.9% | -31 ▲ 43.6% | -12 ▲ 62.7% | -17 ▼ 47.0% | -32 ▼ 84.7% | 2 ▲ 104.8% | |
| Other Comprehensive Income (Net of Tax) | 150 | -4 ▼ 102.8% | 287 ▲ 6936.2% | 5 ▼ 98.3% | 262 ▲ 5420.0% | 736 ▲ 181.1% | 99 ▼ 86.5% | 304 ▲ 206.2% | 1,965 ▲ 547.3% | |
| Total Expenses (incl. D&A & Interest) | 13,364 | 16,591 ▲ 24.1% | 19,427 ▲ 17.1% | 17,757 ▼ 8.6% | 20,372 ▲ 14.7% | 22,522 ▲ 10.6% | 25,162 ▲ 11.7% | 27,248 ▲ 8.3% | 29,035 ▲ 6.6% | |
| Material Cost % of RevenueDerived | 34.12% | 38.06% | 33.44% | 33.57% | 31.43% | 38.83% | 37.16% | 33.84% | 30.62% | |
| Employee Cost % of RevenueDerived | 12.91% | 13.21% | 13.94% | 14.27% | 14.71% | 14.17% | 13.53% | 14.11% | 15.42% | |
| Other Cost % of RevenueDerived | 23.30% | 22.36% | 23.03% | 24.23% | 23.35% | 25.43% | 22.87% | 24.08% | 24.15% | |
| Interest Coverage (x)Derived | 41.36x | 19.82x | 24.15x | 57.43x | 67.03x | 17.61x | 14.92x | 10.79x | 13.20x |
AUROBINDO PHARMA segment analysis : revenue and profit mix.
Disclosed business segments at AUROBINDO PHARMA with their share of revenue and profit, switchable between consolidated and standalone reporting.
AUROBINDO PHARMA discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for AUROBINDO PHARMA.
Our AI distills the core fundamental drivers supporting AUROBINDO PHARMA, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
AUROBINDO PHARMA's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Low debt-to-equity ratio of 0.0018x ensures exceptional financial stability and flexibility.
Operating margin of 15.21% demonstrates solid pricing power and operational efficiency.
Positive operating cash flow of ₹2,885 Cr supports liquidity and dividend sustainability.
Market cap of ₹0.95 LCr ranks among top pharmaceutical peers, indicating significant scale.
Strong cash conversion with OCF/PAT ratio of 1.21x reflects robust earnings quality.
Key Risks.
Latest quarterly EPS grew only 2.0% YoY, indicating sluggish earnings expansion despite revenue.
TTM EPS grew only 1.9% YoY, signaling muted earnings momentum in competitive markets.
Dividend yield of 0.24% is minimal, limiting income appeal for yield-focused investors.
FII holdings fell from 24.12% to 15.33%, signaling foreign investor caution and selling pressure.
ROCE of 9.98% trails peer median of 20.30%, suggesting suboptimal capital deployment efficiency.
Flip Conditions.
Valuation risk. a P/E above 34 (~0.8× the sector multiple of 41.3) would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
AUROBINDO PHARMA peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — AUROBINDO PHARMA is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
AUROBINDO PHARMA chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for AUROBINDO PHARMA — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
AUROBINDO PHARMA delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for AUROBINDO PHARMA over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in AUROBINDO PHARMA stood at 38.9% of traded volume, against a 20-day average of 50.9%.
AUROBINDO PHARMA announcements: results, concalls, ratings, M&A.
Filings AUROBINDO PHARMA sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
AUROBINDO PHARMA files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 262 documents below.
Copy of Newspaper Publication
Aurobindo Pharma Limited has submitted copy of Newspaper Publications.
Acquisition
AUROPHARMA: Aurobindo Pharma Limited has informed the Exchange about incorporation of a new wholly owned subsidiary by the name of Avogent…
Press Release
Aurobindo Pharma Limited has informed the Exchange regarding a press release dated August 31, 2026, titled "Lannett Company LLC, a wholly owned step…
General Updates
Aurobindo Pharma Limited has informed the Exchange about Completion of US FDA Inspection at Unit-VI of Apitoria Pharma Private Limited, a wholly…
Shareholders meeting
Aurobindo Pharma Limited has submitted the Exchange a copy Srutinizers report of AGM held on August 27, 2026. and voting results.
Investor decks & rating reports.
AUROBINDO PHARMA dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue AUROBINDO PHARMA has declared, sequenced by announce and record date.
AUROBINDO PHARMA corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About AUROBINDO PHARMA: business, sector, key facts.
What AUROBINDO PHARMA does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
AUROBINDO PHARMA operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: AUROPHARMA, BSE: 524804.
Aurobindo Pharma Limited is a global biopharmaceutical company with a significant presence in the manufacturing and distribution of generic pharmaceuticals and active pharmaceutical ingredients (APIs). Their operations span several continents, including India, the United States, Europe, and Puerto Rico, showcasing a broad international reach.
The company's product portfolio is extensive and diverse, encompassing a wide range of dosage forms. These include oral solids and liquids, injectables, and vaccines. They also offer over-the-counter (OTC) medications, demonstrating a commitment to serving various healthcare needs. Beyond formulations, Aurobindo Pharma is a major player in the API market, producing crucial ingredients for numerous drugs.
Aurobindo's API production includes a variety of complex molecules and biologicals. They manufacture biosimilars (similar to biological drugs), biocatalysts, peptides, and hormones, demonstrating expertise in advanced pharmaceutical technologies. Their therapeutic focus covers a broad spectrum of medical areas, such as central nervous system disorders, cardiovascular diseases, respiratory illnesses, infections (antibiotics and antiretrovirals), diabetes, gastroenterological issues, cancer (oncology), and dermatological conditions.
A key aspect of Aurobindo Pharma's business is its commitment to addressing significant global health challenges. This is evident in their production of antiretroviral drugs, specifically targeting the needs of HIV-positive adults and children. Furthermore, their contract research and manufacturing services extend across the entire drug lifecycle, from clinical stages to full-scale production. This includes specialized services for the manufacturing of sterile and non-sterile penicillin's, cephalosporins, penems, and non-beta-lactams.
Established in 1986 and headquartered in Hyderabad, India, Aurobindo Pharma has a long history of innovation and growth in the pharmaceutical industry. Their integrated approach, encompassing both formulation and API production, along with their global reach and commitment to various therapeutic areas, positions them as a significant player in the worldwide pharmaceutical market.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AAREY DRUGS & PHARM (AAREYDRUGS) Share PricePeer
- AARTI DRUGS (AARTIDRUGS) Share PricePeer
- AARTI PHARMALABS (AARTIPHARM) Share PricePeer
- AJANTA PHARMA (AJANTPHARM) Share PricePeer
- AKUMS DRUGS AND PHARMA L (AKUMS) Share PricePeer
- Stocks near 52-week high (breakout watch)Screener
- Breakout Trader strategy playbookStrategy
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
Questions investors ask about AUROBINDO PHARMA (AUROPHARMA).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of AUROBINDO PHARMA (AUROPHARMA)?
The current share price of AUROBINDO PHARMA (AUROPHARMA) is ₹1,653.10. Today, the stock has gained by ₹15.80 (0.97%), trading in a range of ₹1,622.60 to ₹1,661.50. The stock opened at ₹1,637.30 with a trading volume of 5,73,938 shares.
02Is AUROBINDO PHARMA stock a good investment for long-term?
AUROBINDO PHARMA can be considered for long-term investment based on several factors. The company has a market capitalization of ₹95,127.23 Cr., P/E ratio of 25.84, ROE of 9.25%, and ROCE of 10.23%. The dividend yield stands at 0%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of AUROBINDO PHARMA stock?
The 52-week high price of AUROBINDO PHARMA (AUROPHARMA) is ₹1,717.00, while the 52-week low is ₹1,033.10. Currently trading at ₹1,653.10, the stock is 60.01% above its 52-week low and 3.72% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy AUROBINDO PHARMA stock at the current price?
Whether to buy AUROBINDO PHARMA stock at ₹1,653.10 depends on multiple factors. The stock is currently trading with a P/E ratio of 25.84 and P/B ratio of 2.54. Today's performance shows a gain of 0.97%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of AUROBINDO PHARMA and when is the next dividend?
AUROBINDO PHARMA offers a dividend yield of 0%, which means for every ₹100 invested at the current price of ₹1,653.10, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of AUROBINDO PHARMA?
AUROBINDO PHARMA's key financial metrics include: P/E Ratio: 25.84, P/B Ratio: 2.54, ROE: 9.25%, ROCE: 10.23%, Dividend Yield: 0%, EPS: ₹17.95, Book Value: ₹658.40, and Debt-to-Equity: 0.2. The company's market cap stands at ₹95,127.23 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is AUROBINDO PHARMA stock performing today in the market?
AUROBINDO PHARMA stock opened at ₹1,637.30 and is currently trading at ₹1,653.10, showing a gain of ₹15.80 (0.97%). The intraday high is ₹1,661.50 and low is ₹1,622.60. The trading volume stands at 5,73,938 shares, indicating moderate market participation today.
08What is the P/E ratio of AUROBINDO PHARMA and what does it indicate?
AUROBINDO PHARMA has a Price-to-Earnings (P/E) ratio of 25.84, which means investors are willing to pay 25.84 for every ₹1 of earnings. With an EPS of ₹17.95, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about AUROBINDO PHARMA (AUROPHARMA) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.